Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Authors
Keywords
-
Journal
CLINICAL ENDOCRINOLOGY
Volume 78, Issue 5, Pages 760-767
Publisher
Wiley
Online
2012-09-26
DOI
10.1111/cen.12057
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib in metastatic thyroid cancer
- (2012) Jaume Capdevila et al. ENDOCRINE-RELATED CANCER
- Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib
- (2011) S. Faivre et al. CLINICAL CANCER RESEARCH
- Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
- (2011) Merina Ahmed et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Bronchial Fistula Associated with Sunitinib in a Patient Previously Treated with Radiation Therapy
- (2010) Damien Basille et al. ANNALS OF PHARMACOTHERAPY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
- (2010) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- Thyroid Cancer Incidence and Survival in the National Cancer Institute Surveillance, Epidemiology, and End Results Race/Ethnicity Groups
- (2010) Guo-Pei Yu et al. THYROID
- 18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study
- (2009) Laetitia Vercellino et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- (2009) Hendrieke Hoftijzer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
- (2009) Maurizio Zangari et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- (2009) David S. Cooper et al. THYROID
- Early Clinical Studies of Novel Therapies for Thyroid Cancers
- (2008) Steven I. Sherman ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib
- (2008) Natascha A.J.B. Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor
- (2008) John O. Prior et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search